Division of Vascular and Endovascular Surgery, Department of Surgery, Massachusetts General Hospital (MGH), 15 Parkman Street, Boston, MA, 02214-3117, USA.
Division of Hematology, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Boston, MA, USA.
Ann Hematol. 2020 Sep;99(9):2113-2118. doi: 10.1007/s00277-020-04169-1. Epub 2020 Jul 12.
This study aimed to determine if there is an association between ABO blood type and severity of COVID-19 defined by intubation or death as well as ascertain if there is variability in testing positive for COVID-19 between blood types. In a multi-institutional study, all adult patients who tested positive for COVID-19 across five hospitals were identified and included from March 6th to April 16th, 2020. Hospitalization, intubation, and death were evaluated for association with blood type. Univariate analysis was conducted using standard techniques and logistic regression was used to determine the independent effect of blood type on intubation and/or death and positive testing. During the study period, there were 7648 patients who received COVID-19 testing throughout the institutions. Of these, 1289 tested positive with a known blood type. A total of 484 (37.5%) were admitted to hospital, 123 (9.5%) were admitted to the ICU, 108 (8.4%) were intubated, 3 (0.2%) required ECMO, and 89 (6.9%) died. Of the 1289 patients who tested positive, 440 (34.2%) were blood type A, 201 (15.6%) were blood type B, 61 (4.7%) were blood type AB, and 587 (45.5%) were blood type O. On univariate analysis, there was no association between blood type and any of the peak inflammatory markers (peak WBC, p = 0.25; peak LDH, p = 0.40; peak ESR, p = 0.16; peak CRP, p = 0.14) nor between blood type and any of the clinical outcomes of severity (admission p = 0.20, ICU admission p = 0.94, intubation p = 0.93, proning while intubated p = 0.58, ECMO p = 0.09, and death p = 0.49). After multivariable analysis, blood type was not independently associated with risk of intubation or death (referent blood type A; blood type B: AOR: 0.72, 95% CI: 0.42-1.26, blood type AB: AOR: 0.78, CI: 0.33-1.87, blood type O: AOR: 0.77, CI: 0.51-1.16), rhesus factor positive (Rh+): AOR: 1.03, CI: 0.93-1.86. Blood type A had no correlation with positive testing (AOR: 1.00, CI: 0.88-1.13), blood type B was associated with higher odds of testing positive for disease (AOR: 1.28, CI: 1.08-1.52), AB was also associated with higher odds of testing positive (AOR: 1.37, CI: 1.02-1.83), and O was associated with a lower risk of testing positive (AOR: 0.84, CI: 0.75-0.95). Rh+ status was associated with higher odds of testing positive (AOR: 1.23, CI: 1.003-1.50). Blood type was not associated with risk of intubation or death in patients with COVID-19. Patients with blood types B and AB who received a test were more likely to test positive and blood type O was less likely to test positive. Rh+ patients were more likely to test positive.
这项研究旨在确定 ABO 血型与 COVID-19 严重程度(定义为插管或死亡)之间是否存在关联,并确定血型之间 COVID-19 检测阳性是否存在差异。在一项多机构研究中,从 2020 年 3 月 6 日至 4 月 16 日,确定并纳入了所有在五家医院检测出 COVID-19 阳性的成年患者。评估住院、插管和死亡与血型的关系。使用标准技术进行单变量分析,并使用逻辑回归确定血型对插管和/或死亡以及阳性检测的独立影响。在研究期间,共有 7648 名患者在各机构接受 COVID-19 检测。其中,1289 人已知血型检测呈阳性。共有 484 人(37.5%)住院,123 人(9.5%)入住 ICU,108 人(8.4%)插管,3 人(0.2%)需要 ECMO,89 人(6.9%)死亡。在 1289 名检测呈阳性的患者中,440 人(34.2%)为血型 A,201 人(15.6%)为血型 B,61 人(4.7%)为血型 AB,587 人(45.5%)为血型 O。单变量分析显示,血型与任何峰值炎症标志物(峰值白细胞计数、p=0.25;峰值乳酸脱氢酶、p=0.40;峰值 ESR、p=0.16;峰值 CRP、p=0.14)之间均无关联,也与严重程度的任何临床结局(入院、p=0.20;入住 ICU、p=0.94;插管、p=0.93;插管时俯卧位、p=0.58;ECMO、p=0.09;死亡、p=0.49)之间均无关联。多变量分析后,血型与插管或死亡的风险无关(参照血型 A;血型 B:比值比 0.72,95%CI:0.42-1.26;血型 AB:比值比 0.78,CI:0.33-1.87;血型 O:比值比 0.77,CI:0.51-1.16),Rh 因子阳性(Rh+):比值比 1.03,CI:0.93-1.86。血型 A 与阳性检测无相关性(比值比 1.00,CI:0.88-1.13),血型 B 与疾病阳性检测的几率更高相关(比值比 1.28,CI:1.08-1.52),AB 也与更高的阳性检测几率相关(比值比 1.37,CI:1.02-1.83),O 型血与阳性检测几率较低相关(比值比 0.84,CI:0.75-0.95)。Rh+ 状态与更高的阳性检测几率相关(比值比 1.23,CI:1.003-1.50)。血型与 COVID-19 患者的插管或死亡风险无关。血型为 B 和 AB 的患者进行检测时更有可能呈阳性,而 O 型血的患者呈阳性的可能性较小。Rh+ 患者更有可能呈阳性。